Overview
The recent success of GLP-1 (glucagon-like peptide-1) receptor agonists drugs in achieving weight loss has put obesity into the spotlight as a chronic disease that requires comprehensive management. Despite these initial positive outcomes, the long-term benefits of these obesity treatments are still under scrutiny.
In this ActiGraph white paper, we review the promising developments and challenges in the rapidly evolving landscape of obesity treatments. We discuss how wearable digital health technologies (DHTs) can help researchers capture objective, continuous data on physical activity, physical functioning, and sleep to fill existing gaps in obesity clinical research.
What You'll Learn
- The evolving landscape of obesity management
- Opportunities for future obesity treatments beyond weight loss
- Payer challenges in GLP-1 drug pricing
- The role of wearables in monitoring functional outcomes in obesity clinical trials